Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 85 peer-reviewed journal articles Updated
Neurology

Understanding Your Child's CMD Diagnosis

At a Glance

Congenital Muscular Dystrophy (CMD) is a group of genetic conditions causing muscle weakness from birth. Because CMD includes many subtypes with varying impacts on the muscles and brain, getting a specific genetic diagnosis is the most vital step to tailor your child's medical care and support.

Hearing that your baby has “low muscle tone” or is “floppy” can be an overwhelming and frightening experience for any parent. This initial observation often leads to a diagnosis of Congenital Muscular Dystrophy (CMD). CMD is not a single disease, but rather an “umbrella term” used to describe a group of genetic muscle-wasting conditions that begin at or very shortly after birth [1][2].

Because CMD is rare, many local pediatricians or general doctors may have never treated a child with this condition. This rarity can make the diagnostic journey feel slow or confusing, but understanding the basics can help you navigate your child’s care with confidence.

What is Congenital Muscular Dystrophy?

CMD is characterized by hypotonia (decreased muscle tone, often called “floppiness”), muscle weakness, and delays in motor development, such as sitting up or crawling [3][4]. Unlike other forms of muscular dystrophy that may appear later in childhood, CMD symptoms are present in early infancy [5].

The condition occurs because of mutations (changes) in specific genes that are responsible for the health and function of muscle cells [6]. These genetic changes interfere with the way muscles grow and repair themselves.

Learn more about Early Warning Signs and Symptoms

Understanding the “Umbrella”

Modern medicine has shifted away from using the broad term “CMD” toward more specific, genetic names. You may hear your doctors use terms like “Related Dystrophies” to describe the specific type your child has [7]. The most common subtypes include:

  • LAMA2-related muscular dystrophy (LAMA2-RD): Also known as Merosin-deficient CMD [8].
  • Collagen VI-related dystrophies (COL6-RD): Which includes Ullrich CMD [9].
  • Dystroglycanopathies: A group that includes conditions like Walker-Warburg syndrome and Muscle-Eye-Brain disease [10].

Learn more about Diagnosing CMD and Finding Your Subtype

Muscle vs. Brain: What to Expect

One of the most common questions parents ask is how CMD will affect their child’s intelligence and learning. The answer depends heavily on the specific genetic subtype:

  • Preserved Cognition: In many common forms, such as LAMA2-RD and COL6-RD, cognitive function is typically preserved [3][11]. While these children may face significant physical challenges, their ability to learn, think, and communicate is often unaffected.
  • Brain Involvement: In other subtypes, particularly the dystroglycanopathies, the genetic change affects both the muscles and the development of the brain [12]. This can lead to intellectual disabilities, seizures, or structural brain differences [13].

The Typical Course

There is currently no cure for CMD, but proactive, specialized symptom management can profoundly impact a child’s quality of life and health. CMD is a lifelong condition, and the “typical” course varies widely. Some children may have a stable or very slowly progressive course, while others may face more rapid challenges with breathing or heart function [14][15].

Because these conditions are complex and affect multiple systems, current Standard of Care (SoC) guidelines emphasize a “multidisciplinary” approach [1]. This means your child will likely be cared for by a team of specialists, including neurologists, physical therapists, and respiratory doctors, to ensure they have the best possible support from day one.

Learn more about Building a Standard of Care for Your Child

Getting a specific genetic “name” for your child’s condition is the most important step in understanding their prognosis, preparing for standard of care, and building a supportive medical team [3][16].

Learn more about Building Your Child’s CMD Care Team
Learn more about Monitoring and Daily Life with CMD

In this guide

5 chapters

01

Early Warning Signs and Symptoms

Learn the early warning signs of Congenital Muscular Dystrophy (CMD) in babies. Understand hypotonia (floppy baby), missed milestones, and common misdiagnoses.

02

Diagnosing CMD and Finding Your Subtype

Learn the steps for diagnosing Congenital Muscular Dystrophy (CMD). Understand the role of genetic testing, CK levels, MRIs, and the top five CMD subtypes.

03

Building a Standard of Care for Your Child

Learn the standard of care for Congenital Muscular Dystrophy (CMD). Understand respiratory support, G-tubes, cardiac monitoring, and anesthesia safety.

04

Building Your Child's CMD Care Team

Learn how to build a multidisciplinary care team for congenital muscular dystrophy (CMD). Discover which specialists your child needs and how to prepare.

05

Monitoring and Daily Life with CMD

Learn how to manage daily life with Congenital Muscular Dystrophy (CMD). Discover proactive monitoring schedules, sick day plans, and school IEP strategies.

Common questions in this guide

What are the early signs of Congenital Muscular Dystrophy in a baby?
The most common early signs are low muscle tone (hypotonia) and muscle weakness. Parents often notice their baby feels unusually floppy or experiences delays in reaching basic motor milestones like sitting up or crawling.
Will Congenital Muscular Dystrophy affect my child's intelligence?
The impact on cognition depends entirely on the specific genetic subtype. In common forms like LAMA2-RD and COL6-RD, intelligence and learning are typically fully preserved. However, subtypes like dystroglycanopathies can affect both muscle and brain development.
How is the specific type of CMD diagnosed?
Doctors use specialized genetic testing to identify the exact gene mutation causing the muscle weakness. Knowing the specific genetic variant is essential for understanding your child's prognosis and establishing the correct care plan.
Is there a cure for Congenital Muscular Dystrophy?
Currently, there is no cure for CMD, but proactive symptom management can significantly improve a child's quality of life. Treatment involves a multidisciplinary team of specialists managing respiratory, physical, and neurological health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific genetic subtype of CMD does my child have, and how was this confirmed?
  2. 2.Is our local hospital equipped to manage the specific respiratory or cardiac needs associated with this subtype, or should we be seen at a regional neuromuscular center?
  3. 3.Based on my child's specific genetic variant, what should we expect regarding their cognitive development and brain health?
  4. 4.Has my child's creatine kinase (CK) level been tested, and how does that number help guide our understanding of their condition?
  5. 5.Are there current consensus care guidelines for this specific subtype that we can share with our local pediatrician?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    283rd ENMC international workshop: Establishing expert care recommendations for LAMA2-RD: A prototype for the development of congenital muscular dystrophy subtype-specific care guidelines. Hoofddorp, The Netherlands, January 17th-19th 2025.

    Zambon AA, Klein A, Sarkozy A, et al.

    Neuromuscular disorders : NMD 2025; (55()):106220 doi:10.1016/j.nmd.2025.106220.

    PMID: 41106238
  2. 2

    Congenital muscular dystrophies: What is new?

    Zambon AA, Muntoni F

    Neuromuscular disorders : NMD 2021; (31(10)):931-942 doi:10.1016/j.nmd.2021.07.009.

    PMID: 34470717
  3. 3

    Broadening the paradigm of laminin α2-related muscular dystrophy: A case of partial merosin deficiency with compound heterozygous variants.

    Tavasoli A, Eghdami S, Kachuei M, Rouzbeh S

    SAGE open medical case reports 2025; (13()):2050313X251366020 doi:10.1177/2050313X251366020.

    PMID: 40874012
  4. 4

    Compound Heterozygous Variants of GOSR2 Associated With Congenital Muscular Dystrophy and Progressive Myoclonus Epilepsy: A Case Report.

    Arroyo MS, Fuller C, Schorry EK, et al.

    Neurology. Genetics 2024; (10(4)):e200177 doi:10.1212/NXG.0000000000200177.

    PMID: 39035823
  5. 5

    Compound heterozygous variants in GOSR2 associated with congenital muscular dystrophy: A case report.

    Henige H, Kaur S, Pappas K

    European journal of medical genetics 2021; (64(4)):104184 doi:10.1016/j.ejmg.2021.104184.

    PMID: 33639315
  6. 6

    A mouse model of inherited choline kinase β-deficiency presents with specific cardiac abnormalities and a predisposition to arrhythmia.

    Tavasoli M, Feridooni T, Feridooni H, et al.

    The Journal of biological chemistry 2022; (298(3)):101716 doi:10.1016/j.jbc.2022.101716.

    PMID: 35151687
  7. 7

    Congenital Muscular Dystrophy and Congenital Myopathy.

    Butterfield RJ

    Continuum (Minneapolis, Minn.) 2019; (25(6)):1640-1661 doi:10.1212/CON.0000000000000792.

    PMID: 31794464
  8. 8

    Clinical and Genetic Landscape of Children With Congenital Muscular Dystrophies From North India.

    Basu A, Suthar R, Pandey A, et al.

    Journal of child neurology 2026; (41(5)):674-699 doi:10.1177/08830738251374530.

    PMID: 40982308
  9. 9

    Electrical impedance myography discriminates congenital muscular dystrophy from controls.

    Schwartz DP, Dastgir J, Salman A, et al.

    Muscle & nerve 2016; (53(3)):402-6 doi:10.1002/mus.24770.

    PMID: 26179210
  10. 10

    Intellectual disability in paediatric patients with genetic muscle diseases.

    Specht S, Straub V

    Neuromuscular disorders : NMD 2021; (31(10)):988-997 doi:10.1016/j.nmd.2021.08.012.

    PMID: 34736636
  11. 11

    Novel LAMA2 variants identified in a patient with white matter abnormalities.

    Yamamoto-Shimojima K, Ono H, Imaizumi T, Yamamoto T

    Human genome variation 2020; (7()):16 doi:10.1038/s41439-020-0103-5.

    PMID: 32509318
  12. 12

    Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy.

    Jahncke JN, Miller DS, Krush M, et al.

    eLife 2024; (12()).

    PMID: 38179984
  13. 13

    Exocyst-mediated membrane trafficking of the lissencephaly-associated ECM receptor dystroglycan is required for proper brain compartmentalization.

    Yatsenko AS, Kucherenko MM, Xie Y, et al.

    eLife 2021; (10()).

    PMID: 33620318
  14. 14

    Dropped head congenital muscular dystrophy caused by de novo mutations in LMNA.

    Karaoglu P, Quizon N, Pergande M, et al.

    Brain & development 2017; (39(4)):361-364 doi:10.1016/j.braindev.2016.11.002.

    PMID: 27876398
  15. 15

    Characteristic Cochlear Hypoplasia in Patients with Walker-Warburg Syndrome: A Radiologic Study of the Inner Ear in α-Dystroglycan-Related Muscular Disorders.

    Talenti G, Robson C, Severino MS, et al.

    AJNR. American journal of neuroradiology 2021; (42(1)):167-172 doi:10.3174/ajnr.A6858.

    PMID: 33122211
  16. 16

    Genetic blueprint of congenital muscular dystrophies with brain malformations in Egypt: A report of 11 families.

    Safwat S, Flannery KP, El Beheiry AA, et al.

    Neurogenetics 2024; (25(2)):93-102 doi:10.1007/s10048-024-00745-z.

    PMID: 38296890

This page provides an overview of Congenital Muscular Dystrophy (CMD) for educational purposes. Always consult your child's pediatric neurologist or neuromuscular specialist for an accurate diagnosis and personalized care plan.

Get notified when new evidence is published on Congenital muscular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.